Morgan Hakki
Overview
Explore the profile of Morgan Hakki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Xu Q, Tan F, Deng Y, Hakki M, Shelburne S, et al.
bioRxiv
. 2024 Oct;
PMID: 39416193
Infections with antimicrobial resistant pathogens, such as are a frequent occurrence in healthcare settings. Human infections are predominantly caused by a small number of sequence types (ST), such as ST235,...
2.
Egge S, Rizvi S, Simar S, Alcalde M, Martinez J, Hanson B, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0012724.
PMID: 38995033
The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space....
3.
Fontana L, Hakki M, Ozer E, Laird A, Strasfeld L
Infect Control Hosp Epidemiol
. 2024 Feb;
45(7):847-855.
PMID: 38385257
Objective: To evaluate the impact of an intervention to limit dispersal from wastewater drain (WWD) sites on meropenem-nonsusceptible patient and environmental colonization and bloodstream infection (BSI) on a hematopoietic cell...
4.
Egge S, Rizvi S, Simar S, Alcalde M, Martinez J, Hanson B, et al.
bioRxiv
. 2024 Feb;
PMID: 38352536
The siderophore-cephalosporin cefiderocol(FDC) presents a promising treatment option for carbapenem-resistant (CR) (PA). FDC circumvents traditional porin and efflux mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space....
5.
Egge S, Lewis 2nd J, Hakki M
Antimicrob Agents Chemother
. 2023 Jul;
67(8):e0066323.
PMID: 37395652
Multidrug-resistant/extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa (PA) are critical antimicrobial resistance threats. Despite their increasing prevalence, treatment options for metallo-β-lactamase (MBL)-producing PA are limited, especially for New Delhi metallo-β-lactamase (NDM) producers....
6.
Fontana L, Strasfeld L, Hakki M
Blood Adv
. 2023 May;
7(15):4035-4038.
PMID: 37216281
No abstract available.
7.
Lewis 2nd J, Wiederhold N, Hakki M, Thompson 3rd G
Antimicrob Agents Chemother
. 2022 Aug;
66(9):e0017722.
PMID: 35969068
Isavuconazole is the newest of the clinically available advanced generation triazole antifungals and is active against a variety of yeasts, molds, and dimorphic fungi. Its current FDA-approved indications include the...
8.
Zhang L, Tan F, Strasfeld L, Hakki M, Kirienko N
Front Cell Infect Microbiol
. 2022 Jul;
12:904602.
PMID: 35782141
An epidemiological study uncovered that fluoroquinolone (FQ) neutropenic prophylaxis in hematopoietic cell transplant and hematologic malignancy (HCT/HM) patients was associated with breakthrough bloodstream infections (BSIs) with isolates non-susceptible to both...
9.
Bergas A, Albasanz-Puig A, Fernandez-Cruz A, Machado M, Novo A, van Duin D, et al.
Microbiol Spectr
. 2022 Apr;
10(3):e0229221.
PMID: 35475683
We sought to assess the characteristics and outcomes of neutropenic hematologic patients with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-tazobactam (C/T). We conducted a multicenter, international, matched-cohort study...
10.
Fontana L, Hakki M
JAC Antimicrob Resist
. 2021 Oct;
3(3):dlab125.
PMID: 34661107
Background: Systematic studies pertaining to the emergence of resistance during therapy of bloodstream infections (BSIs) in haematopoietic cell transplant (HCT) recipients and haematological malignancy (HM) patients are lacking. Objectives: To...